Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

pimavanserin tartrate

NUPLAZID

pimavanserin tartrate (NUPLAZID) is a serotonin 2a (5-ht2a) receptor inverse agonist. Associated with Acadia Pharmaceuticals B.V.. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 20
Pipeline programs 21
News articles 0
Drug details — pimavanserin tartrate
US status
approved
Class
—
Route
ORAL
Patents
20
Programs
21
Data quality
0.89
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

pimavanserin tartrate (NUPLAZID) is a serotonin 2a (5-ht2a) receptor inverse agonist. Associated with Acadia Pharmaceuticals B.V.. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN pimavanserin tartrate
Brand NUPLAZID
Mechanism Serotonin 2a (5-HT2a) receptor inverse agonist
Target 5-hydroxytryptamine receptor 2A
Route ORAL
Formulation CAPSULE
Originator Acadia Pharmaceuticals B.V.

Mechanism of action

Serotonin 2a (5-HT2a) receptor inverse agonist

Primary target: 5-hydroxytryptamine receptor 2A

Approval history

Authority Status Date
FDA approved —

Pipeline programs

Search pipeline Sponsor programs
  1. Pimavanserin Phase 3 · Acadia Pharmaceuticals · Schizophrenia
  2. Pimavanserin Phase 3 · Acadia Pharmaceuticals · Neuropsychiatric Symptoms Related to Neurodegenerative Disea
  3. Pimavanserin Phase 3 · Acadia Pharmaceuticals · Irritability Associated With Autism Spectrum Disorder
  4. Pimavanserin Phase 3 · Acadia Pharmaceuticals · Adjunctive Treatment of Major Depressive Disorder
  5. Pimavanserin tartrate (ACP-103) Phase 3 · Acadia Pharmaceuticals · Parkinson's Disease Psychosis
  6. pimavanserin tartrate Phase 3 · Acadia Pharmaceuticals · Parkinson's Disease Psychosis
  7. ACP-103-070 Phase 2 · Anaxis Pharma · Irritability associated with autistic disorder in children a
  8. Active drug: pimavanserin 17mg (2 strength tablets) Phase 2 · Acadia Pharmaceuticals · Parkinson Disease

Related & competitor drugs

Browse all drugs
  1. cyclobenzaprine hydrochloride Serotonin 2c (5-HT2c) receptor antagonist
  2. trazodone hydrochloride Serotonin 2a (5-HT2a) receptor antagonist

Related patents

Browse patents Acadia Pharmaceuticals B.V. patent hub

  1. US 11844764

    Agitation process for preparing a carbetocin drug product

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11464768

    Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis

    Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11452721

    Formulations of pimavanserin

    Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11191757

    Combination of pimavanserin and cytochrome P450 modulators

    Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11135211

    Pimavanserin for treating impulse control disorder

    Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10953000

    Combination of pimavanserin and cytochrome P450 modulators

    Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10849891

    Formulations of pimavanserin

    Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10646480

    Formulations of pimavanserin

    Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10525046

    Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

    Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10517860

    Combination of pimavanserin and cytochrome P450 modulators

    Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10449185

    Formulations of pimavanserin

    Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10028944

    Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

    Expires Mon Jul 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9757366

    Methods for the treatment of parkinson's disease psychosis using pimavanserin

    Expires Mon Sep 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9670209

    Muscarinic agonists

    Expires Mon Jun 01 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9566271

    Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

    Expires Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9522906

    Tetrahydroquinoline analogues as muscarinic agonists

    Expires Mon Dec 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9446037

    Methods for the treatment of parkinson's disease psychosis using pimavanserin

    Expires Mon Sep 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9296694

    Azacyclic compounds

    Expires Mon Mar 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9211289

    Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

    Expires Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9050343

    Combination of pimavanserin and risperidone for the treatment of psychosis

    Expires Mon Jun 04 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is pimavanserin tartrate?

pimavanserin tartrate (NUPLAZID) is a serotonin 2a (5-ht2a) receptor inverse agonist. Associated with Acadia Pharmaceuticals B.V.. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for pimavanserin tartrate?

NUPLAZID is a marketed brand name for pimavanserin tartrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of pimavanserin tartrate?

pimavanserin tartrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.